An international collaborative study to discontinue Imatinib/Glivec in pediatric CML patients with sustained complete molecular response

Trial Profile

An international collaborative study to discontinue Imatinib/Glivec in pediatric CML patients with sustained complete molecular response

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2016

At a glance

  • Drugs Imatinib (Primary) ; Protein tyrosine kinase inhibitors
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms STOPIMAPED
  • Most Recent Events

    • 01 Dec 2012 New source identified and integrated (European Clinical Trials Database, EudraCT2011-006239-44).
    • 02 Oct 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.
    • 18 Jun 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top